Evidence map›Paper›PMID 37025429›Full record

ArticleIndian journal of clinical biochemistry : IJCB2023

Association of Catechol-O-Methyltransferase Gene Polymorphisms and Haplotypes in the Levodopa-Induced Adverse Events in Subjects with Parkinson's Disease.

Tasneem Sd Fatima, Syed Tazeem Fathima, Rukmini Mridula Kandadai, Rupam Borgohain, Boddupally Sreenu, Vijay Kumar Kutala

Open access · greenAbstract read
In one paragraph

Article in Indian journal of clinical biochemistry : IJCB, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Pharmacogenetics in advanced Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Tasneem Sd FatimaDepartment of Clinical Pharmacology and Therapeutics, Nizam's Institute of Medical Sciences, Hyderabad, Telangana 500082 India.
Syed Tazeem FathimaDepartment of Neurology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana 500082 India.
Rukmini Mridula KandadaiDepartment of Neurology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana 500082 India.
Rupam BorgohainDepartment of Neurology, Nizam's Institute of Medical Sciences, Hyderabad, Telangana 500082 India.
Boddupally SreenuDepartment of Clinical Pharmacology and Therapeutics, Nizam's Institute of Medical Sciences, Hyderabad, Telangana 500082 India.
Vijay Kumar KutalaDepartment of Biochemistry, Nizam's Institute of Medical Sciences, Hyderabad, Telangana 500082 India.ORCID 0000-0002-7253-8999
Nizam's Institute of Medical Sciences · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The presence of dyskinesia is the most common side effect of chronic administration of levodopa in Parkinson's disease (PD) subjects. Genetic polymorphisms in levodopa metabolizing gene, catechol-O-methyl transferase (COMT), is shown to influence the inter-individual variability in drug response and adverse events. In the present study, the association of COMT rs6269, rs4633, rs4818, and rs4680 polymorphisms and haplotypes on pharmacokinetics and adverse events with levodopa was investigated in 150 PD patients. The age of onset of PD was 58.00 ± 10 yrs. The most common side effect faced by 78% of the subjects was dyskinesia. The AUC of levodopa was found to be significantly higher in subjects with dyskinesia (1695 ± 113 ng/ml/hr,

Indexed as

COMTDyskinesiaLevodopaParkinson’s diseasePharmacogeneticsPharmacokinetics

Identifiers

PMID37025429
PMCPMC10070583
OpenAlexW4225269060

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.